StockData
Bioventus Inc. logo

Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 2, 2026Score 13/3041% below fair value
$10.62+0.02 (+0.19%)

Close on Nov 18, 2026Market cap $893.06MP/E 13.8Yield –

Bioventus net income

Net income is the profit left for shareholders after every expense, interest and tax.

Bioventus's net income for the twelve months ending Jun 27, 2026 was $54.46M. For fiscal 2025 it was $22.73M. The highest annual figure on record is $22.73M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$22.73M–
FY2024Dec 31, 2024-$36.13M–
FY2023Dec 31, 2023-$156.23M–
FY2022Dec 31, 2022-$158.70M-919.1%
FY2021Dec 31, 2021$19.38M+18.1%
FY2020Dec 31, 2020$16.41M+139.5%
FY2019Dec 31, 2019$6.85M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$33.44M+348.3%
Q1 FY2026Mar 28, 2026$3.11M–
Q4 FY2025Dec 31, 2025$14.76M–
Q3 FY2025Sep 27, 2025$3.16M–
Q2 FY2025Jun 28, 2025$7.46M–
Q1 FY2025Mar 29, 2025-$2.64M–
Q4 FY2024Dec 31, 2024-$388.00K–
Q3 FY2024Sep 28, 2024-$5.17M–
Q2 FY2024Jun 29, 2024-$25.68M–
Q1 FY2024Mar 30, 2024-$4.89M–
Q4 FY2023Dec 31, 2023-$6.10M–
Q3 FY2023Sep 30, 2023-$7.30M–
Q2 FY2023Jul 1, 2023-$3.68M–
Q1 FY2023Apr 1, 2023-$139.15M–
Q4 FY2022Dec 31, 2022-$31.93M–
Q3 FY2022Oct 1, 2022-$108.25M–
Q2 FY2022Jul 2, 2022-$7.25M–
Q1 FY2022Apr 2, 2022-$11.28M-145.2%
Q4 FY2021Dec 31, 2021-$364.00K-113.1%
Q3 FY2021Oct 2, 2021-$1.07M-112.7%
Q2 FY2021Jul 3, 2021-$4.13M–
Q1 FY2021Apr 3, 2021$24.94M+127.9%
Q4 FY2020Dec 31, 2020$2.78M–
Q3 FY2020Sep 26, 2020$8.46M–
Q2 FY2020Jun 27, 2020-$5.77M–
Q1 FY2020Mar 28, 2020$10.94M–

More Bioventus figures

See a number that looks wrong?